Unknown

Dataset Information

0

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.


ABSTRACT: Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gadolinium-enhancing lesions on T1 weighted MRI brain, within 6 months after fingolimod 0.5 mg/day was stopped. Treatment with a short course of subcutaneous cladribine 60 mg led to effective suppression of inflammatory activity and partial recovery with no short-term safety issues or adverse events.

SUBMITTER: Alvarez-Gonzalez C 

PROVIDER: S-EPMC5497536 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.

Alvarez-Gonzalez Cesar C   Adams Ashok A   Mathews Joela J   Turner Benjamin P BP   Giovannoni Gavin G   Baker David D   Schmierer Klaus K  

Annals of clinical and translational neurology 20170517 7


Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gadolinium-enhancing lesions on T<sub>1</sub> weighted MRI brain, within 6 months after fingolimod 0.5 mg/  ...[more]

Similar Datasets

| S-EPMC8803993 | biostudies-literature
| S-EPMC5722776 | biostudies-literature
| S-EPMC8842147 | biostudies-literature
| S-EPMC6472227 | biostudies-literature
| S-EPMC7557793 | biostudies-literature
| PRJNA966951 | ENA
| S-EPMC6984410 | biostudies-literature
2024-06-20 | GSE231587 | GEO
2019-11-08 | GSE140106 | GEO
| S-EPMC4425257 | biostudies-other